News Releases Year None20242023202220212020 Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon Apr 23, 2024 Tarsus to Participate at Upcoming Investor Conferences Mar 05, 2024 Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis Mar 05, 2024 Tarsus Announces Pricing of $100.0 Million Public Offering Mar 01, 2024 Tarsus Announces Proposed $100.0 Million Public Offering Feb 29, 2024 Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements Feb 27, 2024 Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease Feb 22, 2024 Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 Feb 20, 2024 Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference Jan 31, 2024 Presentations Tarsus Corporate Presentation March 27, 2024 Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with DemodexMites Topline Data Presentation December 11, 2023 XDEMVY Approval Webcast Presentation July 25, 2023 Creating the Next Potential Blockbuster Category in Eye Care June 15, 2023 Tarsus Saturn-2 Phase 3 Trial Topline Results Presentation May 4, 2022 Revolutionizing Treatment for Demodex Blepharitis Patients Webcast Presentation February 10, 2022
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with DemodexMites Topline Data Presentation December 11, 2023